Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04056247 | Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments(PROPHETIC) | active not recruiting | — | 10,000 | OncoHost Ltd.INDUSTRY | 5 | Oct 15, 2025 | clinicaltrials |
| NCT04139902 | Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma | active not recruiting | Phase 2 | 48 | Diwakar DavarOTHER | 1 |
| Oct 15, 2025 |
| clinicaltrials |
| NCT05598853 | Intrathecal Double Checkpoint Inhibition(IT-IO) | active not recruiting | Phase 1 | 26 | University of ZurichOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT06540391 | A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients(MELODY-1) | active not recruiting | Phase 1 | 41 | Microbiotica LtdINDUSTRY | 4 | Sep 26, 2025 | clinicaltrials |
| NCT05933577 | A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) | active not recruiting | Phase 3 | 1,089 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 24, 2025 | clinicaltrials |
| NCT05309421 | A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma | active not recruiting | Phase 2 | 17 | Evaxion Biotech A/SINDUSTRY | 2 | Sep 22, 2025 | clinicaltrials |
| NCT05653882 | A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | active not recruiting | Phase 1 | 552 | Asher Biotherapeutics, Inc.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT03470922 | A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma(RELATIVITY-047) | active not recruiting | Phase 2 / Phase 3 | 714 | Bristol-Myers SquibbINDUSTRY | 25 | Sep 9, 2025 | clinicaltrials |
| NCT04283890 | PHP and Immunotherapy in Metastasized UM(CHOPIN) | active not recruiting | Phase 1 / Phase 2 | 83 | Leiden University Medical CenterOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06551064 | Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients(Dahlia) | active not recruiting | Phase 1 | 96 | Formycon AGINDUSTRY | 11 | Sep 4, 2025 | clinicaltrials |
| NCT05585320 | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 209 | Immuneering CorporationINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05155254 | IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) | active not recruiting | Phase 3 | 407 | IO BiotechINDUSTRY | 16 | Aug 28, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT03611868 | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 230 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT05222932 | Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1(AVENTIL) | active not recruiting | Phase 1 | 15 | TILT Biotherapeutics Ltd.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT03235245 | Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib(EBIN) | active not recruiting | Phase 2 | 271 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Aug 1, 2025 | clinicaltrials |
| NCT05061134 | A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition(MONETTE) | active not recruiting | Phase 2 | 194 | AstraZenecaINDUSTRY | 11 | Jul 31, 2025 | clinicaltrials |
| NCT05315258 | Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma(TebeMRD) | active not recruiting | Phase 2 | 850 | University of OxfordOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05751928 | A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma(NEO-MIMAJOR) | active not recruiting | Phase 3 | 411 | BiocadINDUSTRY | 2 | Jul 8, 2025 | clinicaltrials |
| NCT06112808 | A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin | active not recruiting | Phase 1 | 300 | BiocadINDUSTRY | 2 | Jul 8, 2025 | clinicaltrials |
| NCT06640530 | Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin(UNIVERSE) | active not recruiting | Phase 3 | 392 | BiocadINDUSTRY | 3 | Jul 8, 2025 | clinicaltrials |
| NCT05286294 | Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders(MITRIC) | active not recruiting | Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT05180799 | A Phase 1/2 Study of BA3071 in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 320 | BioAtla, Inc.INDUSTRY | 2 | Jun 15, 2025 | clinicaltrials |
| NCT02743819 | Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma | active not recruiting | Phase 2 | 70 | University of ChicagoOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT05592639 | VideoEndoscopic Radical Inguinal Lymphadenectomy for Penile Cancer(VELRAD) | active not recruiting | N/A | 50 | University College, LondonOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT04385732 | Melanoma Surveillance Photography (MSP) to Improve Early Detection of Melanoma in Ultra-high and High Risk Patients(IMAGE) | active not recruiting | N/A | 670 | Melanoma and Skin Cancer Trials LimitedOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT03719131 | Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy | active not recruiting | Phase 2 | 15 | Emory UniversityOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04706962 | TH1902 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 70 | TheratechnologiesINDUSTRY | 2 | Apr 15, 2025 | clinicaltrials |
| NCT06014619 | Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs | active not recruiting | — | 500 | Maastricht University Medical CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT03772899 | Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic) | active not recruiting | Phase 1 | 20 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05736523 | Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA) | active not recruiting | — | 28 | University of UtahOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06863870 | Assessment of Circulating Tumor Cells and microRNAs in Patients With Metastatic Non-cutaneous Melanoma | active not recruiting | — | 35 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT05732805 | A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma(OCTAVA) | active not recruiting | Phase 3 | 270 | BiocadINDUSTRY | 3 | Feb 27, 2025 | clinicaltrials |
| NCT03757689 | Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma | active not recruiting | Phase 2 | 63 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06809491 | One-year Recurrence-free Survival of Melanoma Patients Eligible for a Sentinel Lymph Node Biopsy(MELASENTI) | active not recruiting | — | 200 | Central Hospital, Nancy, FranceOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 272 | Checkpoint Therapeutics, Inc.INDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT04565769 | Cognitive Function in Melanoma Patients Treated With Adjuvant Immune Checkpoint Inhibitors | active not recruiting | — | 100 | Aarhus University HospitalOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT03553836 | Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) | active not recruiting | Phase 3 | 976 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Nov 29, 2024 | clinicaltrials |
| NCT02385214 | MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma(MelMarT) | active not recruiting | N/A | 400 | Melanoma and Skin Cancer Trials LimitedOTHER | 5 | Nov 27, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT02938299 | Neoadjuvant L19IL2/L19TNF- Pivotal Study(Pivotal) | active not recruiting | Phase 3 | 214 | Philogen S.p.A.INDUSTRY | 4 | Sep 19, 2024 | clinicaltrials |
| NCT04205227 | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 137 | ENB Therapeutics, IncINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT04309409 | Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma(NivoMela) | active not recruiting | Phase 3 | 374 | University Hospital, EssenOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT04949113 | Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma(NADINA) | active not recruiting | Phase 3 | 423 | The Netherlands Cancer InstituteOTHER | 3 | Mar 8, 2024 | clinicaltrials |
| NCT05022901 | An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma | active not recruiting | Phase 3 | 30 | Delcath Systems Inc.INDUSTRY | 1 | Dec 21, 2023 | clinicaltrials |
| NCT01942603 | Minimal SN Tumor Burden(Minitub) | active not recruiting | — | 296 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 10 | Nov 28, 2023 | clinicaltrials |
| NCT05270044 | Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.(COLUMBUS-AD) | active not recruiting | Phase 3 | 815 | Pierre Fabre MedicamentINDUSTRY | 23 | Nov 22, 2023 | clinicaltrials |
| NCT02068196 | A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.(Ipi4) | active not recruiting | Phase 4 | 150 | Oslo University HospitalOTHER | 1 | Mar 24, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Oct 15, 2025source: clinicaltrials